Researchers observed an increase in both CXCR4 and CD5 levels as the cells progressed to later stages of the cell cycle, particularly in the S/G2/M phases.

The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline ...

The study enrolled 523 patients with untreated CLL, randomly assigning them to receive either MRD-driven ibrutinib-venetoclax therapy or standard FCR. After a median follow-up of 43.7 months ...